Skip to content

Myriad Genetics MYGN Common Stock Par Value Per Share

Common Stock Par Value Per Share at other companies

NeoGenomics logo
NeoGenomicsNEO
$0.000.0%
Veracyte logo
VeracyteVCYT
$0.000.0%
GeneDx Holdings logo
GeneDx HoldingsWGS
$0.000.0%
Castle Biosciences logo
Castle BiosciencesCSTL
$0.000.0%
Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's common stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's common stock par value per share?
Myriad Genetics (MYGN) reported common stock par value per share of $0.01 in Q1 2026.
How has Myriad Genetics's common stock par value per share changed year-over-year?
Myriad Genetics's common stock par value per share decreased by 0.0% year-over-year, from $0.01 to $0.01.
What does common stock par value per share mean?
The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.